---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-055420"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2021-10-29T23:59:59+00:00"
generated_at: "2026-06-28T16:10:22.771900+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CorMedix CFO Matt David appointed interim CEO; salary to $425k, bonus 60%

## Summary
- Dr. David's base salary rises from $330k to $425k during interim CEO period; after, it resets to $375k.
- Target annual bonus increased to 60% of base salary while interim CEO; thereafter 40%.
- Severance extended to 12 months of base salary if terminated without cause during interim CEO role.
- Board grants Dr. David a stock option for 125,000 shares, vesting over four years.
- Board has initiated search with a leading executive firm for a permanent CEO.

## SEC filing metadata
- accession: 0001213900-21-055420
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2021-10-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390021055420/0001213900-21-055420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390021055420/ea149576-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-055420
- JSON: https://secwatch.observer/filing/0001213900-21-055420.json
- Plain text: https://secwatch.observer/filing/0001213900-21-055420.txt

## Key facts
- Executive change
  Matt David was appointed as interim Chief Executive Officer at CorMedix Inc..
  - Action: appointed
  - Role: interim Chief Executive Officer
  source text: On October 26, 2021, CorMedix Inc. (“Company”) and Matt David, M.D., the Company’s current Chief Financial Officer, entered into a letter agreement (the “Letter Agreement”) modifying certain terms of his employment agreement with the Company, dated May 11, 2020 (“Employment Agreement”), and providing other compensation, as a result of Dr. David serving as interim Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390021055420/0001213900-21-055420-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.